Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
CAPECITABINE
MINT PHARMACEUTICALS INC
L01BC06
CAPECITABINE
500MG
TABLET
CAPECITABINE 500MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0134120002; AHFS:
APPROVED
2020-11-17
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MINT-CAPECITABINE Capecitabine Tablets Tablets, 150 mg and 500 mg USP Antineoplastic Agent Mint Pharmaceuticals Inc. 6575 Davand Drive Mississauga, ON, L5T 2M3 Canada Date of Initial Authorization: November 17, 2020 Date of Revision: June 28, 2022 Submission Control No: 260947 _Product Monograph MINT-CAPECITABINE _ _ _ _Page 2 of 66 _ RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 06/2022 7 WARNINGS AND PRECAUTIONS 06/2022 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations 06/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ................................................................................................................4 1.1 Pediatrics ............................................................................................................5 1.2 Geriatrics.............................................................................................................5 2 CONTRAINDICATIONS ...................................................................................................5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ..............................................................6 4 DOSAGE AND ADMINISTRATION...................................................................................6 4.1 Dosing Considerations .........................................................................................6 4.2 Recommended Dose and Dosage Adjustment.......................................................7 4.5 Missed Dose ........................................ Prečítajte si celý dokument